Charles Wallace

“I'm for R.K. So for my first question, I was wondering how should we think about the R&D span going forward, you know, fourth quarter and then also 2027 with the placebo-controlled portion of, you know, Azure 1 and 4 studies completing?”

“I think, so the first question I have, so you called out that any Platinum Pro unit sold in 2026 is going to have an embedded credit towards Proteus.”

“And, Dan, congrats on all you've done for ElectroCore, and it was great working with you. Thank you. So, for my first question, with the changes with management and the new hiring of Michael Fox and increased responsibilities for Joshua, I wanted to better understand these new leadership dynamics.”

“So, on the seasonality, you mentioned that the procedure growth and also the site activation may be weighted in this back half. But as you add more patients from these sites, do you expect that the discount will expand from the current 10%?”

“So I guess a question on the guidance from me. So in 2025, the sales grew about 55%, and the guidance range implies a 21% to 25% annual growth. So I was wondering if you could provide some color on how much of this is driven by Livmarly versus the bio-acid portfolio.”